Akeso

This study tests whether combining two experimental drugs, AK112 and VG2025, can safely shrink tumors in people with advanced colorectal cancer that has spread to the liver. About 72 adults who have already tried at least one standard treatment will receive the combination. The m…

This study tests a new medicine called AK139 for people with moderate-to-severe eczema (atopic dermatitis). About 168 adults will receive either AK139 or a placebo to see if it safely improves skin symptoms like itching and rash. The goal is to find a better treatment option for …

This phase 3 study tests whether a shot (subcutaneous) form of the drug AK104 works as well as the IV form when combined with chemotherapy for advanced stomach or gastroesophageal junction cancer. About 422 people who have not had prior treatment for their advanced cancer will ta…

This study tests a combination of two experimental drugs, AK146D1 and AK112, in 200 people with advanced HER2-negative breast cancer that cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. This is a Phase 2 trial, meaning it …

This study tests an experimental drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 with measurable tumors and adequate organ…

This early-phase trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tum…

This study tests a new drug called AK112 in people with a specific type of lung cancer (non-squamous non-small cell) that has certain genetic changes. Participants must have already tried and failed a standard targeted therapy (TKI). The goal is to see if AK112 can shrink tumors …

This study tests a new drug called AK139 in 160 adults with moderate to severe asthma. The goal is to see if it improves lung function and reduces airway inflammation safely. Participants will receive either AK139 or a placebo, and researchers will monitor side effects and immune…

This study tests a new medicine called AK139 for people with moderate to severe seasonal allergic rhinitis (hay fever). About 111 adults aged 18 to 65 with at least a 2-year history of seasonal allergies will receive either AK139 or a placebo. The main goal is to see if AK139 red…

This early-stage study tests the safety and tolerability of a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The trial will also measure how the drug moves through the body and whether it triggers an immune response. About 108 participants will t…